Sentiment-Signal
20,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Unternehmen & Branche
| Name | Shattuck Labs, Inc. |
|---|---|
| Ticker | STTK |
| CIK | 0001680367 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 360,9 Mio. USD |
| Beta | 1,29 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,000,000 | -48,809,000 | -0.70 | 91,026,000 | 82,390,000 |
| 2025-09-30 | 10-Q | 1,000,000 | -10,056,000 | -0.14 | 100,333,000 | 93,240,000 |
| 2025-06-30 | 10-Q | 0 | -12,458,000 | -0.24 | 64,371,000 | 57,019,000 |
| 2025-03-31 | 10-Q | 0 | -13,702,000 | -0.27 | 77,167,000 | 67,586,000 |
| 2024-12-31 | 10-K | 5,721,000 | -75,410,000 | -1.49 | 91,049,000 | 79,626,000 |
| 2024-09-30 | 10-Q | 2,997,000 | -16,675,000 | -0.33 | 111,720,000 | 96,577,000 |
| 2024-06-30 | 10-Q | 1,609,000 | -21,552,000 | -0.42 | 128,614,000 | 110,616,000 |
| 2024-03-31 | 10-Q | 1,115,000 | -18,504,000 | -0.37 | 146,335,000 | 128,813,000 |
| 2023-12-31 | 10-K | 1,657,000 | -87,298,000 | -2.05 | 159,564,000 | 144,705,000 |
| 2023-09-30 | 10-Q | 686,000 | -27,541,000 | -0.65 | 130,457,000 | 112,783,000 |
| 2023-06-30 | 10-Q | 200,000 | -21,346,000 | -0.50 | 155,270,000 | 138,458,000 |
| 2023-03-31 | 10-Q | 57,000 | -20,724,000 | -0.49 | 177,677,000 | 157,654,000 |
| 2022-12-31 | 10-K | 652,000 | -101,945,000 | -2.41 | 205,324,000 | 176,157,000 |
| 2022-09-30 | 10-Q | 212,000 | -24,635,000 | -0.58 | 222,943,000 | 199,418,000 |
| 2022-06-30 | 10-Q | 50,000 | -27,371,000 | -0.65 | 251,340,000 | 222,529,000 |
| 2022-03-31 | 10-Q | 0 | -24,528,000 | -0.58 | 270,490,000 | 248,938,000 |
| 2021-12-31 | 10-K | 30,017,000 | -44,974,000 | -1.07 | 298,585,000 | 271,786,000 |
| 2021-09-30 | 10-Q | 1,900,000 | -17,410,000 | -0.41 | 310,568,000 | 261,166,000 |
| 2021-06-30 | 10-Q | -4,231,000 | -23,598,000 | -0.56 | 323,780,000 | 277,087,000 |
| 2021-03-31 | 10-Q | 2,270,000 | -11,813,000 | -0.28 | 336,850,000 | 298,662,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-25 | ORBIMED ADVISORS LLC | Director | Open Market Purchase | 1,051,021 | 0.87 | 911,970.92 | +33,3% | |
| 2025-08-25 | ORBIMED ADVISORS LLC | Director | Open Market Purchase | 5,255,106 | 0.87 | 4,559,855.48 | +166,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.